Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
1
|
Boceprevir for untreated chronic HCV genotype 1 infection.
|
N Engl J Med
|
2011
|
19.01
|
2
|
Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection.
|
N Engl J Med
|
2009
|
14.31
|
3
|
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options.
|
N Engl J Med
|
2013
|
8.49
|
4
|
Response-guided telaprevir combination treatment for hepatitis C virus infection.
|
N Engl J Med
|
2011
|
6.31
|
5
|
Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus.
|
Gastroenterology
|
2010
|
6.14
|
6
|
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
|
N Engl J Med
|
2014
|
3.40
|
7
|
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
|
Lancet Infect Dis
|
2013
|
3.30
|
8
|
Presentation and outcome of hepatocellular carcinoma in HIV-infected patients: a U.S.-Canadian multicenter study.
|
J Hepatol
|
2007
|
2.58
|
9
|
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
|
N Engl J Med
|
2014
|
2.54
|
10
|
Serum cholesterol and statin use predict virological response to peginterferon and ribavirin therapy.
|
Hepatology
|
2010
|
2.53
|
11
|
Needlestick injuries among surgeons in training.
|
N Engl J Med
|
2007
|
2.37
|
12
|
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study.
|
Gastroenterology
|
2004
|
2.28
|
13
|
Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
|
Hepatology
|
2014
|
2.17
|
14
|
Concordance of sustained virological response 4, 12, and 24 weeks post-treatment with sofosbuvir-containing regimens for hepatitis C virus.
|
Hepatology
|
2014
|
2.04
|
15
|
Factors that predict response of patients with hepatitis C virus infection to boceprevir.
|
Gastroenterology
|
2012
|
1.95
|
16
|
Daclatasvir plus Sofosbuvir for HCV in Patients Coinfected with HIV-1.
|
N Engl J Med
|
2015
|
1.94
|
17
|
Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV.
|
JAMA
|
2012
|
1.88
|
18
|
Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa.
|
Am J Gastroenterol
|
2003
|
1.83
|
19
|
Limited effectiveness of antiviral treatment for hepatitis C in an urban HIV clinic.
|
AIDS
|
2006
|
1.82
|
20
|
Effects of ribavirin dose reduction vs erythropoietin for boceprevir-related anemia in patients with chronic hepatitis C virus genotype 1 infection--a randomized trial.
|
Gastroenterology
|
2013
|
1.63
|
21
|
Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients.
|
J Hepatol
|
2011
|
1.59
|
22
|
Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus.
|
Gastroenterology
|
2010
|
1.53
|
23
|
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 1.
|
Gastroenterology
|
2010
|
1.35
|
24
|
Antiretroviral therapy using zidovudine, lamivudine, and efavirenz in South Africa: tolerability and clinical events.
|
AIDS
|
2008
|
1.32
|
25
|
Management of patients coinfected with HCV and HIV: a close look at the role for direct-acting antivirals.
|
Gastroenterology
|
2012
|
1.31
|
26
|
Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.
|
Hepatology
|
2004
|
1.30
|
27
|
Racial differences in hepatitis C treatment eligibility.
|
Hepatology
|
2011
|
1.28
|
28
|
A framework for understanding factors that affect access and utilization of treatment for hepatitis C virus infection among HCV-mono-infected and HIV/HCV-co-infected injection drug users.
|
AIDS
|
2005
|
1.25
|
29
|
Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.
|
Hepatology
|
2012
|
1.19
|
30
|
The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection.
|
Hepatology
|
2005
|
1.17
|
31
|
Treatment of chronic hepatitis C: a systematic review.
|
Hepatology
|
2002
|
1.14
|
32
|
The effect of HAART and HCV infection on the development of hyperglycemia among HIV-infected persons.
|
J Acquir Immune Defic Syndr
|
2003
|
1.13
|
33
|
Fibrosis progression in human immunodeficiency virus/hepatitis C virus coinfected adults: prospective analysis of 435 liver biopsy pairs.
|
Hepatology
|
2014
|
1.08
|
34
|
Daclatasvir plus sofosbuvir for HCV infection.
|
N Engl J Med
|
2014
|
1.04
|
35
|
Kupffer cells are depleted with HIV immunodeficiency and partially recovered with antiretroviral immune reconstitution.
|
AIDS
|
2009
|
1.00
|
36
|
Viral clearance is associated with improved insulin resistance in genotype 1 chronic hepatitis C but not genotype 2/3.
|
Gut
|
2011
|
1.00
|
37
|
All-oral combination of ledipasvir, vedroprevir, tegobuvir, and ribavirin in treatment-naïve patients with genotype 1 HCV infection.
|
Hepatology
|
2014
|
0.98
|
38
|
Antiretroviral-associated liver injury.
|
Clin Liver Dis
|
2003
|
0.97
|
39
|
Lessons from HIV therapy applied to viral hepatitis therapy: summary of a workshop.
|
Am J Gastroenterol
|
2010
|
0.95
|
40
|
A Phase I/II study evaluating escalating doses of recombinant human albumin-interferon-alpha fusion protein in chronic hepatitis C patients who have failed previous interferon-alpha-based therapy.
|
Antivir Ther
|
2006
|
0.93
|
41
|
Treatment of chronic hepatitis B in HIV-infected persons: thinking outside the black box.
|
Clin Infect Dis
|
2005
|
0.93
|
42
|
Provisional guidance on the use of hepatitis C virus protease inhibitors for treatment of hepatitis C in HIV-infected persons.
|
Clin Infect Dis
|
2012
|
0.93
|
43
|
Protective interleukin-28B genotype affects hepatitis C virus clearance, but does not contribute to HIV-1 control in a cohort of African-American elite controllers/suppressors.
|
AIDS
|
2011
|
0.92
|
44
|
Efficacy and safety of peginterferon alfa-2a/ribavirin in methadone maintenance patients: randomized comparison of direct observed therapy and self-administration.
|
Am J Gastroenterol
|
2008
|
0.91
|
45
|
Steatosis is an independent predictor of relapse following rapid virologic response in patients with HCV genotype 3.
|
Clin Gastroenterol Hepatol
|
2011
|
0.91
|
46
|
Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection.
|
J Hepatol
|
2011
|
0.90
|
47
|
Stability of liver fibrosis among HCV-infected injection drug users.
|
Antivir Ther
|
2012
|
0.89
|
48
|
Hepatitis C virus in the setting of HIV or hepatitis B virus coinfection.
|
Semin Liver Dis
|
2004
|
0.88
|
49
|
Epoetin alfa once weekly improves anemia in HIV/hepatitis C virus-coinfected patients treated with interferon/ribavirin: a randomized controlled trial.
|
J Acquir Immune Defic Syndr
|
2005
|
0.85
|
50
|
Hepatic profile analyses of tipranavir in Phase II and III clinical trials.
|
BMC Infect Dis
|
2009
|
0.85
|
51
|
Analysis of site performance in academic-based and community-based centers in the IDEAL Study.
|
J Clin Gastroenterol
|
2013
|
0.85
|
52
|
Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.
|
Liver Int
|
2013
|
0.84
|
53
|
Vitamin D deficiency and its relation to bone mineral density and liver fibrosis in HIV-HCV coinfection.
|
Antivir Ther
|
2012
|
0.83
|
54
|
Insulin resistance predicts re-treatment failure in an efficacy study of peginterferon-α-2a and ribavirin in HIV/HCV co-infected patients.
|
J Hepatol
|
2010
|
0.82
|
55
|
Cost-effectiveness of peginterferon alfa-2a (40kDa) plus ribavirin in patients with HIV and hepatitis C virus co-infection.
|
J Clin Virol
|
2006
|
0.79
|
56
|
Hepatic steatosis associated with increased central body fat by dual-energy X-ray absorptiometry and uncontrolled HIV in HIV/hepatitis C co-infected persons.
|
AIDS
|
2010
|
0.78
|
57
|
Modulation of interferon-specific gene expression by albumin-interferon-alpha in interferon-alpha-experienced patients with chronic hepatitis C.
|
Antivir Ther
|
2006
|
0.77
|
58
|
Defining the standard of care: randomized controlled trials for the treatment of hepatitis C in the HIV-infected person.
|
Hepatology
|
2004
|
0.77
|
59
|
Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.
|
Clin Gastroenterol Hepatol
|
2008
|
0.77
|
60
|
Hepatitis C trials that combine investigational agents with pegylated interferon should be stratified by interleukin-28B genotype.
|
Hepatology
|
2010
|
0.76
|
61
|
Hepatitis C virus: a critical appraisal of new approaches to therapy.
|
Hepat Res Treat
|
2012
|
0.76
|
62
|
Regression of splenic lymphoma after treatment of hepatitis C virus infection.
|
N Engl J Med
|
2002
|
0.75
|
63
|
Antiretroviral therapy, interferon sensitivity, and virologic setpoint in human immunodeficiency virus/hepatitis C virus coinfected patients.
|
Hepatology
|
2014
|
0.75
|
64
|
Predictors of consent to pharmacogenomics testing in the IDEAL study.
|
Pharmacogenet Genomics
|
2013
|
0.75
|
65
|
Infections during peginterferon/ribavirin therapy are associated with the magnitude of decline in absolute lymphocyte count: results of the IDEAL study.
|
Clin Infect Dis
|
2014
|
0.75
|
66
|
Global transcriptional effects of PEG-IFN-alpha and ribavirin on peripheral blood cells obtained from patients with chronic hepatitis C.
|
Hepatol Res
|
2006
|
0.75
|
67
|
Should a prisoner be placed on the organ transplant waiting list?
|
Virtual Mentor
|
2008
|
0.75
|
68
|
Detection of liver disease in injection drug users.
|
J Addict Dis
|
2008
|
0.75
|